Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An in silico Analysis

Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An in silico Analysis

The novel coronavirus SARS-CoV-2 disease “COVID-19” emerged in China and rapidly spread to other countries; due to its rapid worldwide spread, the WHO has declared this as a global emergency. As there is no specific treatment prescribed to treat COVID-19, the seeking of suitable therapeutics among e...

Full description

Bibliographic Details
Main Authors: Rajaiah Alexpandi, Joelma Freire De Mesquita, Shunmugiah Karutha Pandian, Arumugam Veera Ravi
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-07-01
Series:Frontiers in Microbiology
Subjects:
drug repurposing
SARS-CoV-2
main-protease (3CLpro)
RNA-dependent RNA-polymerase
spike-ACE2 complex
quinoline based-drugs
Online Access:https://www.frontiersin.org/article/10.3389/fmicb.2020.01796/full

Similar Items

Similar Items